ArticleLeukemia2012
Mast cells promote the growth of Hodgkin's lymphoma cell tumor by modifying the tumor microenvironment that can be perturbed by bortezomib.
Article in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 42 citations in OpenAlex.
- CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality.Journal of hematology & oncology · 2026Review
- Review
- Immune and stromal transcriptional patterns that influence the outcome of classic Hodgkin lymphoma.Scientific reports · 2024Article
- Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications.Biology · 2023Review
- Inflammatory microenvironment in classical Hodgkin's lymphoma with special stress on mast cells.Frontiers in oncology · 2022Review
- Hodgkin Lymphoma: A Special Microenvironment.Journal of clinical medicine · 2021Review
- Review
- Asthma-related inflammation promotes lung metastasis of breast cancer cells through CCL11-CCR3 pathway.Respiratory research · 2021Article
- Steering Mast Cells or Their Mediators as a Prospective Novel Therapeutic Approach for the Treatment of Hematological Malignancies.Frontiers in oncology · 2021Review
- Role of Mast Cells in Shaping the Tumor Microenvironment.Clinical reviews in allergy & immunology · 2020Review
- Drug Resistance in Non-Hodgkin Lymphomas.International journal of molecular sciences · 2020Review
- Mast Cell Activation and KSHV Infection in Kaposi Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018Article
- Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells.Cancer discovery · 2017Article
- Microenvironmental interactions between endothelial and lymphoma cells: a role for the canonical WNT pathway in Hodgkin lymphoma.Leukemia · 2017Article
- Role of mast cells in fibrosis of classical Hodgkin lymphoma.International journal of immunopathology and pharmacology · 2016Article
- Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- Fibroblast Growth Factor-2 facilitates the growth and chemo-resistance of leukemia cells in the bone marrow by modulating osteoblast functions.Scientific reports · 2016Article
- The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy.Leukemia · 2015Article
- Histone deacetylase-3 mediates positive feedback relationship between anaphylaxis and tumor metastasis.The Journal of biological chemistry · 2014Article
- Tumor microvessel density-associated mast cells in canine nodal lymphoma.SAGE open medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hodgkin's lymphoma is frequently associated with mast cell infiltration that correlates directly with disease severity, but the mechanisms underlying this relationship remain unclear. Here, we report that mast cells promote the growth of Hodgkin's tumor by modifying the tumor microenvironment. A transplantation assay shows that primary murine mast cells accelerate tumor growth by established Hodgkin's cell lines, and promote marked neovascularization and fibrosis. Both mast cells and Hodgkin's cells were sensitive to bortezomib, but mast cells were more resistant to bortezomib. However, bortezomib inhibited degranulation, PGE(2)-induced rapid release of CCL2, and continuous release of vascular endothelial growth factor-A from mast cells even at the concentration that did not induce cell death. Bortezomib-treated mast cells lost the ability to induce neovasculization and fibrosis, and did not promote the growth of Hodgkin tumor in vivo. These results provide further evidence supporting causal relationships between inflammation and tumor growth, and demonstrate that bortezomib can target the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.